FOXD1 activates KIFC1 to modulate aerobic glycolysis and reinforce cisplatin resistance of breast cancer
Reproductive Biology · 2025
DOI: 10.1016/j.repbio.2024.100969 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive Biology, 2025. Verfasst von Haitao Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery Department, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang 455000, China. Hauptthemen laut MEDLINE: Cisplatin, Drug Resistance, Neoplasm, Forkhead Transcription Factors, Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Breast cancer (BC) is the most prevalent invasive malignant tumor. Cisplatin (DDP) is a prototype of platinum-based chemotherapy drugs, its resistance severely hinders its clinical application. This project intended to figure out the exact mechanism of KIFC1 in the DDP resistance of BC. METHODS: The levels of KIFC1 and FOXD1 in BC as well as their binding sites were investigated by bioinformatics analysis. The signaling pathways regulated by FOXD1 were analyzed. Chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays verified the binding relationship between the two. Through quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blot (WB), we assessed the expression of FOXD1, KIFC1, and glycolysis-related genes. CCK-8 assay was applied in the determination of cell viability to assess the efficacy of DDP resistance. Extracellular acidification rate (ECAR), glucose consumption, lactate synthesis, Adenosine triphosphate (ATP) content, and oxygen consumption rate (OCR) were measured to evaluate glycolysis. RESULTS: FOXD1 and KIFC1 were significantly upregulated in BC, with KIFC1 being significantly enriched in the glycolysis pathway. Overexpression of KIFC1 significantly enhanced the DDP resistance of BC cells, while promoting aerobic glycolysis. Mechanistically, FOXD1 was bound to the promoter of KIFC1 to activate its transcription. Its overexpression counteracted the inhibitory effect of KIFC1 knockdown on the DDP resistance of BC cells. CONCLUSION: FOXD1 activates the glycolysis pathway by upregulating KIFC1, thereby facilitating BC cells' DDP resistance. Therefore, the FOXD1/KIFC1 axis linked the glycolysis pathway to DDP resistance and may be a promising new target for reinforcing DDP resistance in BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Surgery Department, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang 455000, China.
- General Surgery Department, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang 455000, China. Electronic address: wiweiya@163.com.
Zitieren
APA
Gao, H., Wang, J., Liu, J., Wang, H., Wang, T., Li, S., Niu, L., & Wei, Y. (2025). FOXD1 activates KIFC1 to modulate aerobic glycolysis and reinforce cisplatin resistance of breast cancer. Reproductive Biology. https://doi.org/10.1016/j.repbio.2024.100969
Vancouver
Gao H, Wang J, Liu J, Wang H, Wang T, Li S, et al. FOXD1 activates KIFC1 to modulate aerobic glycolysis and reinforce cisplatin resistance of breast cancer. Reproductive Biology. 2025. doi:10.1016/j.repbio.2024.100969
BibTeX
@article{Gao2025,
author = {Gao, Haitao and Wang, Jing and Liu, Jiacai and Wang, Huihua and Wang, Tiantian and Li, Sha and Niu, Lili and Wei, Ya},
title = {FOXD1 activates KIFC1 to modulate aerobic glycolysis and reinforce cisplatin resistance of breast cancer},
journal = {Reproductive Biology},
year = {2025},
doi = {10.1016/j.repbio.2024.100969}
}
EUVIMED